Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $175.0 million
Deal Type : Acquisition
Astellas completes acquisition of Propella Therapeutics
Details : Through the acquisition, Astellas has acquired PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
December 21, 2023
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $175.0 million
Deal Type : Acquisition
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $175.0 million
Deal Type : Acquisition
Astellas to Acquire Propella Therapeutics
Details : Through the acquisition of Propella, Astellas will acquire PRL-02 (abiraterone decanoate), a next-generation androgen biosynthesis inhibitor being developed by Propella to treat prostate cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Astellas Pharma
Deal Size : $175.0 million
Deal Type : Acquisition
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRL-02 (abiraterone decanoate) is routed through the lymph to target tissues where it releases the precise level of abiraterone needed to block CYP17 lyase for 12 weeks, thereby reducing interim tumor breakthrough risk.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : Abiraterone Decanoate,Dexamethasone,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PRL-02 (abiraterone decanoate), is long-acting, selective CYP17 lyase inhibitor that has been designed for optimal uptake through lymphatic system so that a precise level of abiraterone can be released to continuously block CYP17 lyase over a three-month...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 09, 2022
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the terms of the agreement, ASK Pharm will have exclusive rights to develop, manufacture and commercialize CGS-200-5 for the Greater China region. Topical CGS-200-5 has clinically been shown to significantly reduce OA knee pain.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Undisclosed
July 04, 2022
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Aosaikang Pharmaceutical
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Study Phase : IND Enabling
Recipient : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Partnership
Details : Under this new partnership, Propella and NCI will conduct a multi-center clinical trial to evaluate abiraterone decanoate, as a new therapy for metastatic prostate cancer.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2021
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Recipient : National Cancer Institute
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Propella Therapeutics Granted U.S. Patent for New Treatment for Metastatic Prostate Cancer
Details : The patent covers new molecules that are designed to provide significant advantages over the current standard of care. The patent, titled Abiraterone Prodrugs, protects certain novel prodrugs.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 10, 2020
Lead Product(s) : Abiraterone Decanoate
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CGS-200-1
Therapeutic Area : Musculoskeletal
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
May 17, 2018
Lead Product(s) : CGS-200-1
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Study Phase : Phase IV
Sponsor : Palm Beach Research, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Osteoarthritis Knee Pain Relief Study of 0.25% 920-CGS-200
Details : Undisclosed
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
April 21, 2017
Lead Product(s) : Capsaicin
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase IV
Sponsor : Palm Beach Research, Inc
Deal Size : Inapplicable
Deal Type : Inapplicable